Leap Therapeutics is developing a promising cancer treatment, DKN-01, with encouraging early trial data. However, the company has less than a year's worth of funds, making future financing critical. The phase 2 trial results expected in 2025 are crucial for its valuation, but the immediate financial concerns balance the potential positive impact of the drug's development.